Industry News
Pharmaceutical Industry News
As recent changes to U.S. vaccine…
As recent changes to U.S. vaccine policy face pushback on several fronts, one of the key bodies driving the nation's immunization recommendations is postponing its meeting previously planned for next week.
Throughout 2025, the world’s first…
Throughout 2025, the world's first metabolic dysfunction-associated steatohepatitis (MASH) drug generated just shy of a billion dollars. But Madrigal has much more growth in mind for the years to come.
In a fourth-quarter conference…
In a fourth-quarter conference call, Insmed CEO Will Lewis admitted that it was “audacious” that his company would project sales of newly approved respiratory drug Brinsupri to reach $1 billion in 2026. Then he laid
An untitled letter shared to the…
An untitled letter shared to the agency’s public database this month homes in on certain details of a commercial touting Tremfya’s use in ulcerative colitis.
As Enflonsia approaches the…
As Enflonsia approaches the one-year anniversary of its approval, Merck is padding the case for a label expansion that could see the protective antibody better match Sanofi and AstraZeneca’s rival infant RSV preventive Beyfortus.
Synthetic biology specialist Manus…
Synthetic biology specialist Manus Bio has scored a $15 million contract from the U.S. government to create a domestic supply source for shikimic acid, a key starting material used in the production of influenza drug
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine
Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.
Kennedy’s MAHA Coalition Is a Mess
A political movement cannot survive on spite alone.
With an eye—and ear—toward…
With an eye—and ear—toward spreading the perseverance and optimism ingrained in the field of science, AbbVie has launched a new podcast series touting the work of its own scientists and other experts.
As President Donald Trump attempts…
As President Donald Trump attempts to convince Congress to write his Most Favored Nation drug pricing plan into law, he has received pushback from free-market conservatives. An interview with former Biden administration advisor John Barkett
In what will be the industry’s…
In what will be the industry’s most competitively contested market, FENIX power ranks the Top 10 obesity players positioned to outperform
GRAM’s CEO on specialization,…
GRAM’s CEO on specialization, re-shoring and rising demand in sterile fill manufacturing.
With $55 billion earmarked to…
With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion plans that are aimed, at least in part, at abating the Trump administration’s pharmaceutical
As Recipharm continues to refine…
As Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai Immunotherapeutics.
In his report, Senator Bill…
In his report, Senator Bill Cassidy suggested a slate of changes to the FDA to support broader drug access and to reduce regulatory burdens on drugmakers.
Less than half a year after…
Less than half a year after winning an inaugural green light in chronic hives, Novartis’ oral BTK inhibitor Rhapsido is jockeying to expand its urticaria reach into a new indication where it has the potential
Six weeks after Eli…
Six weeks after Eli Lilly revealed the success of phase 3b trial testing a combination of Zepbound and Taltz in patients with psoriatic arthritis, the Indianapolis company has reported another trial victory with the combination treatment
Eli Lilly is partnering on Team…
Eli Lilly is partnering on Team USA’s push to help Olympic athletes hurdle the challenges of recovering from injury. And, with increased awareness of the program on the agenda, the drugmaker has enlisted former basketball
As it looks ahead to the potential…
As it looks ahead to the potential launch of its sustained-delivery treatment Duravyu for wet age-related macular degeneration and diabetic macular edema, EyePoint has tapped a new commercial leader with experience heading up ophthalmology franchises
Stada will invest more than 85…
Stada will invest more than 85 million euros (around $101 million) to build a new production facility in Saudi Arabia, which will ultimately serve as a supply hub for the broader Middle East and North